Cell-based gene therapy for advanced pancreatic cancer after chemotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and efficacy of RR001, a cell-based gene therapy, administered to patients with locally advanced pancreatic adenocarcinoma following chemotherapy cycles. The study is open-label and non-randomized, focusing on increasing doses of RR001 derived from the patient's own adipose tissue, genetically modified to produce a potent anti-cancer agent. The goal is to improve treatment outcomes and potentially increase the number of patients eligible for surgical resection, which is currently the only curative option for this condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with confirmed pancreatic ductal adenocarcinoma classified as locally advanced pancreatic adenocarcinoma (LPAC)
* Patients with no evidence of peritoneal or hematogenous metastasis
* Patients classified as non-resectable locally advanced pancreatic carcinoma (LAPC) based on imaging (TC and NMR), on multidisciplinary staff evaluation by at least an oncologist, radiologist and a qualified digestive surgeon and accounting for AJCC/UICC TNM and clinical staging
* Measurable tumor according RECIST criteria v 1.1
* Low tumor burden with at least one lesion equal/less than 3,5 cm that is suitable for US guided injection (and needle biopsy).
* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
* Patients must be eligible for chemotherapy treatment (based on standard of care)
* Patient older than 18 years of age
* Adequate hepatic and kidney function/Safe hematologic profile
* Negative serum pregnancy test for females of childbearing potential within days of starting treatment
* Willingness and ability to comply with the scheduled visits, treatment plan, imaging procedures, laboratory tests and other study procedures, including lipoaspirate collection (liposuction)

Exclusion Criteria:

* Patient with pancreatic cystic tumor or pancreatic pseudocyst
* Patient with pancreatic tumor different from adenocarcinoma (endocrine, metastases)
* Patients with unknown stage or recurrent pancreatic cancer
* Patients with immunosuppression or susceptibility to viral infection
* Patients with HIV, hepatitis B, hepatitis C, HTLV-I/II, Treponema Pallidum infections
* Patients with liver cirrhosis or other documented liver diseases
* Patient contraindication to use chemotherapy treatments
* Previous of radiotherapy and chemotherapy for PDAC
* Previous hematopoietic stem cell or organ transplantation
* Irreversible cardiac arrhythmias requiring permanent medication
* Heart insufficiency (\> grade II, New York Heart Association NYHA criteria)
* History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris
* Uncontrolled hypertension
* Other malignancies within the past 2 years (not including basal cell carcinoma of the skin, prostate cancer or in situ cervix carcinoma, in situ melanoma).
* Active autoimmune disease
* Use of any investigational agents within 21 days from the administration of study treatment
* Patient has had major open surgery prior to the administration of study treatment
* Uncontrolled intercurrent illness including but not limited to psychiatric illness/social situations that in the opinion of the Investigator would compromise compliance of study requirements or put the patient at unacceptable risk
* Suspected or known allergy or hypersensitivity to fluoroquinolones including but not limited to ciprofloxacin
* Suspected or known allergy or hypersensitivity to protamine sulfate or protamine containing products. Including but not limited to patients who have previously undergone procedures such as coronary angioplasty or cardio-pulmonary bypass, which may involve the use of protamine, diabetics who have been treated with protamine insulin, patients allergic to fish, and men who have undergone a vasectomy or are infertile and may have antibodies to protamine

Where it's running

• Azienda Ospedaliero-Universitaria (AOU) Policlinico di Modena
  Modena, Italy, Italy Recruiting

Study contacts

• Study coordinator: Annalisa Fontana
• Email: fontana.annalisa@aou.mo.it
• Phone: IT + 39 0594223808/0594225165

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AB801 with chemotherapy and immunotherapy for cholangiocarcinoma and pancreatic cancer

  This phase 1 study tests whether AB801 can be given safely with chemotherapy and immunotherapy in adults with border-line resectable, locally advanced, or metastatic cholangiocarcinoma or pancreatic cancer.

  Recruiting Phase 1 Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT07619313

• Surgery after tumor-shrinking treatment for locally advanced pancreatic cancer

  This project will test whether doing surgery after at least four months of chemotherapy helps people with locally advanced pancreatic cancer that was initially considered not removable live longer and feel better.

  Recruiting Azienda Ospedaliera di Padova · Padova · NCT07241663

• XER-001 (nasoduodenal amifostine) with SBRT for locally advanced pancreatic cancer

  This trial tests whether giving XER-001 through a nasoduodenal tube together with stereotactic body radiotherapy (SBRT) is safe and helpful for people with locally advanced pancreatic cancer.

  Recruiting at 5 sites Phase 1/2 Xerient Pharma · Duarte, California and 4 other locations · NCT07157033

• Comparing NALIRIFOX to a modified gemcitabine/nab‑paclitaxel/cisplatin regimen for advanced pancreatic adenocarcinoma

  This compares NALIRIFOX to a modified gemcitabine/nab‑paclitaxel/cisplatin regimen to see if it helps people with untreated locally advanced or metastatic pancreatic ductal adenocarcinoma live longer or have better tumor responses.

  Recruiting at 2 sites Phase 2 Medical University of South Carolina · Charleston, South Carolina and 1 other locations · NCT07076212

• Adding panitumumab to chemotherapy for unresectable or metastatic KRAS wild-type pancreatic cancer

  This trial will test whether giving the antibody panitumumab along with standard chemotherapy helps people with unresectable, locally advanced, or metastatic KRAS wild-type pancreatic cancer live longer.

  Recruiting at 272 sites Phase 3 SWOG Cancer Research Network · Anchorage, Alaska and 273 other locations · NCT06998940

• Kinisoquin to prevent blood clots in people with advanced pancreatic cancer

  This trial will test whether Kinisoquin can prevent blood clots in people starting chemotherapy for metastatic or locally advanced pancreatic cancer.

  Recruiting at 3 sites Phase 3 Quercis Pharma AG · Ventura, California and 2 other locations · NCT06861088

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.